Physician profile
Robert M Sexton
NPI 1952656829
$4,204.18
in general payments reported to CMS, 2019-2025
35 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $979 · 2023: $1,157 · 2024: $782 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $475.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $371.72 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $293.94 | 2021-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $230.16 | 2022-2025 | |
| Boston Scientific Corporation | $224.70 | 2023-2025 | Wavewriter Alpha Prime 16, General - Erectile Dysfunction |
| Merck Sharp & Dohme LLC | $201.22 | 2021-2023 | Verquvo, Belsomra, Gardasil 9 |
| Pfizer INC. | $194.08 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $157.13 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $135.54 | 2022-2025 | |
| Lilly USA, LLC | $134.16 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $123.44 | 2021-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.13 | 2021-2023 | Synjardy, Jardiance |
| Xeris Pharmaceuticals, INC. | $82.18 | 2022-2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $73.51 | 2023-2024 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $72.64 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.74 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $66.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.38 | 2024-2025 | Xifaxan, Trulance |
| Philips North America LLC | $53.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $48.40 | 2021-2025 | |
| Amarin Pharma, INC. | $43.43 | 2021 | |
| Eisai INC. | $40.63 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $36.19 | 2021-2022 | |
| Corcept Therapeutics | $28.70 | 2021 | |
| Inspire Medical Systems, INC. | $26.82 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $26.43 | 2024 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $22.45 | 2021 | |
| Indivior INC. | $21.74 | 2022 | |
| Lundbeck LLC | $18.66 | 2024 | Vyepti |
| Edwards Lifesciences Corporation | $15.99 | 2024 | |
| Ibsa Pharma INC. | $15.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.15 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.